Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07281976
PHASE1/PHASE2

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Sponsor: Nanjing Leads Biolabs Co.,Ltd

View on ClinicalTrials.gov

Summary

This trial is an open-label, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple negative breast cancer(TNBC).

Official title: An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 Monotherapy or in Combination With Albumin-bound Paclitaxel in Patients With Recurrent or Metastatic Triple Negative Breast Cancer

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

220

Start Date

2026-01-27

Completion Date

2027-12-31

Last Updated

2026-02-12

Healthy Volunteers

No

Interventions

DRUG

LBL-024 for Injection

Intravenous infusion.

DRUG

albumin-bound Paclitaxel injection

Intravenous infusion.

DRUG

Toripalimab Injection

Intravenous infusion.

Locations (7)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Henan Cancer Hospital

Zhengzhou, Henan, China

Jiangsu Province Hospital

Nanjing, Jiangsu, China

The first hospital of Jilin University

Changchun, Jilin, China

Liaoning Cancer Hospital

Shenyang, Liaoning, China